UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 2, 2021

STRATA SKIN SCIENCES, INC.

(Exact Name of Registrant Specified in Charter)

 

  

  

Registrant's telephone number, including area code:   215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company. ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

On August 2, 2021, Strata Skin Sciences (the “Company”) announced the appointment of Brent Cowgill as Vice President of Marketing. Mr. Cowgill has over 20 years of healthcare sales and marketing experience. Prior to joining the Company he managed Vantage Marketing, a healthcare consulting firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals, and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State University.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

(d)

Exhibits:

99.1 Press release, dated August 2, 2021.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Strata Skin Sciences Announces Appointment of New VP of Marketing

Horsham, Pa., August 2, 2021 — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Brent Cowgill as Vice President of Marketing.

Mr. Cowgill has over 20 years of healthcare sales and marketing experience. Prior to joining STRATA he managed Vantage Marketing, a healthcare consulting firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals, and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State University.

“I am very excited to join the STRATA team,” said Mr. Cowgill. “I look forward to helping STRATA expand its presence within the dermatology market while building upon XTRAC's commercial success as the market’s leading excimer laser technology used to treat several chronic skin conditions that afflict millions of people worldwide.”

About STRATA Skin Sciences, Inc.

---